Biochemical Oncology for Personalized and Precision Medicine

Nadia Hamdy
International Journal of Cancer & Biomedical Research
(IJCBR) https://jcbr.journals.ekb.eg

IJCBR is an Int. journal published by the Egyptian Society of Cancer Research (EACR, established in 2014, http://eacr.tanta.edu.eg) and sponsored by the Egyptian Knowledge Bank (EKB: www.ekb.eg).

IJCBR has been approved by the Supreme Council of Universities, Egypt with score 7 (http://egjournal.scu.eg). The journal is cited by google scholar and registered by Publons (https://publons.com). The journal has recently been evaluated in 2020 by Nature Springer with a good standing.

Scope of IJCBR
- Drug discovery from natural and synthetic resources
- BioMedical applications of nanotechnology
- Stem cell biology and its application
- Basic and applied biotechnology
- Inflammation and autoimmune diseases
- In silico models and bioinformatics
- In vitro and In vivo preclinical animal models
- Cellular and molecular cancer biology
- Cancer Immunology and Immunotherapy
- New methods for prediction, early detection, diagnosis prognosis and treatment of diseases.
- Immunology in health and diseases
- Anti-microbial defense mechanisms
- Cellular and molecular physiology and pathology of diseases

IJCBR Editor,
Prof. Mohamed Labib Salem, PhD
Professor of Immunology
Faculty of Science, Tanta University, Egypt
Biochemical Oncology for Personalized and Precision Medicine

Nadia Hamdy

Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

ABSTRACT

Still cancer treatment is a major challenge to Health Care Sustainability (Egypt Vision 2030). Chemotherapy normo-toxicity as well as multidrug cancer cell resistance raise the debate of “Die Another Day” or “Die Another Way”. This mandates identification of chemo-preventive and/or chemo therapeutic agent(s) that can target most, if not all, “Cancer Hallmarks”, translated into “Drug-Resistance Hallmarks”, in a way that regulates the proliferation of unwanted cancer cells, with minimal side effects or multi-organ toxicity, with prolonged overall survival.

This can be achieved via cutting-edge research such as site-specific delivery cargos, specific rocket targeting using nanotechnology, the use of natural compounds and drug repurposing. This would achieve a green environment in drug design and development, which is the central focus of “Biochemical Oncology Field” for cancer management. This includes cell signaling pathways, maintaining a balance between cell proliferation and death, stemness of cancer cells, epithelial-mesenchymal transition, dysregulation of the cell cycle, tyrosine kinase growth factor signaling pathways. Understanding of these biochemical signatures in cancer would open a new avenue to control altered drug metabolism, featured by “Tumor Micro-Environment”.

Keeping in mind, first, that no single drug can target all cancer hallmarks, affect drug metabolism, drug resistance. Second, no single treatment can target all cancer types or can fit all cancer patients or even one patient with a variety of concomitant diseases or different environmental stressors! Hence, the design and production of chemo-preventive agents acting on these particular molecular targets are of great interest for cancer treatment personalization and precision medicine (Figure 1).

Figure 1. A sketch suggesting how biochemical oncology can target different hallmarks of cancer microenvironment

Editor-in-Chief: Prof. M.L. Salem, PhD - Article DOI: 10.21608/JCBR.2021.69602.1192
Egyptian Association for Cancer Research (EACR)
http://eacr.tanta.edu.eg/

EACR is an NGO society that was declared by the Ministry of Social Solidarity (Egypt) No. 1938 in 19/11/2014 based on the initiative of Prof. Mohamed Labib Salem, the current Chairman of EACR. EACR aims primarily to assist researchers, in particular young researchers in the field of cancer research through workshops, seminars and conferences. Its first international annual conference entitled "Anti-Cancer Drug Discovery" was successfully organized in April 2019 (http://acdd.tanta.edu.eg). Additionally, EACR aims to raise the awareness of the society about the importance of scientific research in the field of cancer research in prediction, early diagnosis and treatment of cancer. EACR is also keen to outreach the scientific community with periodicals and news on cancer research including peer-reviewed scientific journals for the publication of cutting-edge research. The official scientific journal of EACR is "International Journal of Cancer and biomedical Research (IJCBR: https://jcb.r.journals.ekb.eg) was successfully issued in 2017 and has been sponsored by the Egyptian Knowledge Bank (EKB: www.ekb.eg).

EACR Chairman,
Prof. Mohamed Labib Salem, PhD
Professor of Immunology
Faculty of Science, Tanta University, Egypt
International Journal of Cancer & Biomedical Research
(IJCBR) Online ISSN 2682-2628

Editor-in-Chief
Mohamed Labib Salem, PhD
Tanta University, Egypt

Managing Editor
Nehal Elmashad, MD
Tanta University, Egypt
Nabil Mohy Eldin, PhD
Kafrelsheikh University, Egypt
Doaa Al-Ghareeb, PhD
Alexandria University, Egypt
Abdel-Aziz Zidan, PhD
Damanhour University, Egypt
Wesam Meshrif, PhD
Tanta University, Egypt
Rasha Eraky, MD
Tanta University, Egypt

Associate Editor
Hesham Tawfik
Tanta University, Egypt
Mostafa El-Sheekh
Tanta University, Egypt
Youssry Albolkiny, PhD
Tanta University, Egypt
Gamal Badr
Assuit University, Egypt
Elsayed Salim
Tanta University, Egypt
Essam Elshiekh
Tanta Cancer Center, Egypt

Editorial Board
Alberto Montero
Tausig Cancer Center, Cleveland, USA
Marcela Diaz
Cleveland Clinic Foundation, USA
Yi Zhang
Zhengzhou University, China
Shengdian Wang
Chinese Academy of Sciences, China
Faris Alenzi
Prince Sattam bin Abdulaziz University, KSA
Mark Robunstein
Medical University of South Carolina, USA
Mamdooh Ghoneum, DSc
Charles Drew University of Medicine & Science, USA
Natarajan Muthusamy, DVM
The Ohio State University, USA
Hideki Kasuya MD, PhD, FACS
Nagoya University, Japan
Sherif El-Khamisy, MD
Sheffield University, UK
Mohamed Abou-El-Enein, MD
Charité Universitätmedizin Berlin, Germany
Alaa Eldin Almosafta, MD
McGill University, Canada
Amr Amin
United Arab Emirates University, UAE
AbdelRahman Zekri
National Cancer Institute, Egypt
Mohamed Attia, MD
Tanta University, Egypt
Mohamed Eshanshory, MD
Tanta University, Egypt
Hussein Khamis
Alexandria University, Egypt
Magdy Mahfouz
Kaf Elsheikh University, Egypt
Ehab Elbedewey
Tanta University, Egypt
Abeer Badr
Cairo University, Egypt
Nadia Hamdy, PharmD
Ain Shams University, Egypt
Ibrahim El-Sayed
Menoufiya University, Egypt
Tarek Aboul-Fadl, PharmD
Assuit University, Egypt
Mohamed Noureldin
Banha University, Egypt
Haam Abou Elela
National Institute of Oceanography and Fisheries, Egypt
Sameh Ali, MD
Naroda Liver Institute, Egypt
Maha El-Demellawi
City for Scientific Research & Technology Applications, Egypt
Desouky A Abd-El-Haleem
City for Scientific Research & Technology Applications, Egypt
Ashraf Tabll
National Research Center, Egypt
Wael Lotfy, MD
Alexandria University, Egypt
Olfat Gadallah, MD
Tanta University, Egypt
Nahla Shoukry
Suez University, Egypt
Medhat Eldenayar
Tanta University, Egypt
Nagla Sarhan, MD
Tanta University, Egypt
Naglaa Fathy, MD
Zagazig University, Egypt
Azza Hasam Mohamed
Menoufiya University, Egypt
Nanees Gamal Eldin
Tanta University, Egypt
Mohamed Mansour, UK
Sabbah Hammoury
Alexandria Ayadi Almostaqbal Oncology Hospital, Egypt
Nehal Aboulfotah
Zewail City for Science and Technology, Cairo, Egypt
Amir Elkhami
Galaxo, San Francisco, USA
Rabab Khairat
National Research Center, Giza, Egypt
Ahmed Alzohairy
Zagazi University, Egypt
Wgady Khalil
National Research Center, Egypt
Sayed Bakry
Alazhar University, Egypt
Mohamed Ghanem, MD
Kaf Elshiekh University, Egypt
Mohamed Salama, MD
Mansoura University, Egypt
Mona Marie, MD
Alexandria University, Egypt

For more information, contact
Hamdi Kandil
Tanta University, Egypt
Email: Ijcbr100@gmail.com